Zhongzhi Pharmaceutical Holdings Ltd. has issued a profit warning, indicating a significant decline in its financial performance for the first half of 2025. The company anticipates a decrease in net profit of approximately 90% compared to the same period in the previous year. This downturn is attributed to adjustments in industry policies that have led to a short-term drop in sales revenue, subsequently affecting profitability. Despite these challenges, the company remains committed to market investment and is actively seeking new business growth opportunities. Shareholders and potential investors are advised to exercise caution when dealing with the company's shares and to await the publication of the full unaudited consolidated results by the end of August 2025.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。